×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
ARTL – artelo biosciences, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
ARTL
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
4/7
07:50 am
artl
Artelo Biosciences Regains Compliance with Nasdaq Listing Requirements
Medium
Report
Artelo Biosciences Regains Compliance with Nasdaq Listing Requirements
3/30
06:01 pm
artl
Artelo Biosciences Announces Closing of $11.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules [Yahoo! Finance]
High
Report
Artelo Biosciences Announces Closing of $11.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules [Yahoo! Finance]
3/30
05:07 pm
artl
Artelo Biosciences Announces Closing of $11.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules [TheStreet.com]
High
Report
Artelo Biosciences Announces Closing of $11.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules [TheStreet.com]
3/30
04:46 pm
artl
Artelo Biosciences Announces Closing of $11.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
High
Report
Artelo Biosciences Announces Closing of $11.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
3/30
06:18 am
artl
Artelo Biosciences (ARTL) had its "sell (e+)" rating reaffirmed by Weiss Ratings.
Medium
Report
Artelo Biosciences (ARTL) had its "sell (e+)" rating reaffirmed by Weiss Ratings.
3/27
10:40 am
artl
Artelo Biosciences Announces $11.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
Medium
Report
Artelo Biosciences Announces $11.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
3/25
04:05 pm
artl
Artelo Biosciences Expands ART27.13 Development as a Potential Companion Therapy to GLP-1 Treatments
High
Report
Artelo Biosciences Expands ART27.13 Development as a Potential Companion Therapy to GLP-1 Treatments
3/25
07:31 am
artl
Artelo Biosciences Expansion into $16.3B Glaucoma Market, Via Fully Funded Study, Highlights Multi-Platform Pipeline Strength
High
Report
Artelo Biosciences Expansion into $16.3B Glaucoma Market, Via Fully Funded Study, Highlights Multi-Platform Pipeline Strength
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
4/16
08:00 am
artl
Form 424B3 ARTELO BIOSCIENCES, INC.
Medium
Report
Form 424B3 ARTELO BIOSCIENCES, INC.
4/16
06:04 am
artl
Form EFFECT ARTELO BIOSCIENCES, INC.
High
Report
Form EFFECT ARTELO BIOSCIENCES, INC.
4/7
04:19 pm
artl
Form S-1 ARTELO BIOSCIENCES, INC.
Medium
Report
Form S-1 ARTELO BIOSCIENCES, INC.
4/7
08:00 am
artl
Form 8-K ARTELO BIOSCIENCES, INC. For: Apr 06
Medium
Report
Form 8-K ARTELO BIOSCIENCES, INC. For: Apr 06
4/3
04:47 pm
artl
Form SCHEDULE 13G ARTELO BIOSCIENCES, INC. Filed by: INTRACOASTAL CAPITAL, LLC
Medium
Report
Form SCHEDULE 13G ARTELO BIOSCIENCES, INC. Filed by: INTRACOASTAL CAPITAL, LLC
3/31
06:14 am
artl
Form EFFECT ARTELO BIOSCIENCES, INC.
High
Report
Form EFFECT ARTELO BIOSCIENCES, INC.
3/30
05:40 pm
artl
Form 8-K ARTELO BIOSCIENCES, INC. For: Mar 27
High
Report
Form 8-K ARTELO BIOSCIENCES, INC. For: Mar 27
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
6/21
Form EFFECT ARTELO BIOSCIENCES, INC.
284.3%
4/14 Artelo Biosciences Reports Second Quarter Fiscal Year 2020 Financial Results and Provides Business Update 31.4%
2/3 Artelo Biosciences Announces NCI Grant of $4.2 Million to Stony Brook University to Advance FABP5 Inhibitor Cancer Program 23.3%
7/9 Artelo Biosciences (NASDAQ: ARTL) is now covered by analysts at Maxim Group. They set a "buy" rating on the stock. 20.1%
6/20 Form S-1/A ARTELO BIOSCIENCES, INC. 15.2%
11/1 Form 4 ARTELO BIOSCIENCES, INC. For: Oct 30 Filed by: Gorgas Gregory D. 9.2%
3/23 Artelo Biosciences to Present at the Spring Investor Summit on March 25th 8.8%
9/11 Artelo Biosciences to Present at the Fall Investor Summit in New York City on September 17th 7.3%
8/30 Form 4 ARTELO BIOSCIENCES, INC. For: Aug 29 Filed by: MATSUI CONNIE 7.2%
6/25 Form 8-K ARTELO BIOSCIENCES, INC. For: Jun 21 6.5%
4/14 Artelo Biosciences Reports Second Quarter Fiscal Year 2020 Financial Results and Provides Business Update 31.4%
2/3 Artelo Biosciences Announces NCI Grant of $4.2 Million to Stony Brook University to Advance FABP5 Inhibitor Cancer Program 23.3%
7/9 Artelo Biosciences (NASDAQ: ARTL) is now covered by analysts at Maxim Group. They set a "buy" rating on the stock. 20.1%
6/20 Form S-1/A ARTELO BIOSCIENCES, INC. 15.2%
11/1 Form 4 ARTELO BIOSCIENCES, INC. For: Oct 30 Filed by: Gorgas Gregory D. 9.2%
3/23 Artelo Biosciences to Present at the Spring Investor Summit on March 25th 8.8%
9/11 Artelo Biosciences to Present at the Fall Investor Summit in New York City on September 17th 7.3%
8/30 Form 4 ARTELO BIOSCIENCES, INC. For: Aug 29 Filed by: MATSUI CONNIE 7.2%
6/25 Form 8-K ARTELO BIOSCIENCES, INC. For: Jun 21 6.5%
TOP News Decliners
10/17
Form 4 ARTELO BIOSCIENCES, INC. For: Oct 15 Filed by: Gorgas Gregory D.
-21.0%
3/11 Form 8-K ARTELO BIOSCIENCES, INC. For: Mar 06 -15.9%
11/25 Artelo Biosciences Reports Fourth Quarter and Fiscal Year 2019 Financial Results and Provides Business Update -15.9%
6/10 Form S-1/A ARTELO BIOSCIENCES, INC. -15.4%
4/15 Form 8-K ARTELO BIOSCIENCES, INC. For: Apr 13 -14.0%
1/15 Form S-3 ARTELO BIOSCIENCES, INC. -13.6%
2/4 Form EFFECT ARTELO BIOSCIENCES, INC. -12.0%
2/14 Form SC 13G ARTELO BIOSCIENCES, INC. Filed by: Moss David J -10.6%
10/30 Form S-3 ARTELO BIOSCIENCES, INC. -9.1%
2/3 Artelo's [MarketWatch] -8.9%
3/11 Form 8-K ARTELO BIOSCIENCES, INC. For: Mar 06 -15.9%
11/25 Artelo Biosciences Reports Fourth Quarter and Fiscal Year 2019 Financial Results and Provides Business Update -15.9%
6/10 Form S-1/A ARTELO BIOSCIENCES, INC. -15.4%
4/15 Form 8-K ARTELO BIOSCIENCES, INC. For: Apr 13 -14.0%
1/15 Form S-3 ARTELO BIOSCIENCES, INC. -13.6%
2/4 Form EFFECT ARTELO BIOSCIENCES, INC. -12.0%
2/14 Form SC 13G ARTELO BIOSCIENCES, INC. Filed by: Moss David J -10.6%
10/30 Form S-3 ARTELO BIOSCIENCES, INC. -9.1%
2/3 Artelo's [MarketWatch] -8.9%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: